Dataset opportunity
Europlaz — 监管记录数据集机会
Europlaz 持有的中等监管记录数据集,可用于监管 RAG 和合规性 Copilots。
Score
63.7
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管事务中的人工智能市场 = 2024 年为 13.1 亿美元,复合年增长率为 18.60%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高(专有)
Accessibility
受限
Legal
混合所有权 — 许可权待明确
Buyer persona
监管科技与合规人工智能供应商
本数据集包含来自医疗器械合同制造商 Europlaz 的文本型监管记录。它包含丰富的 `business_records`(业务记录)、`industrial_data`(工业数据)和监管申报文件,提供了制造过程、质量保证以及符合ISO 13485等标准的详细证据。这些结构化和非结构化数据非常适合训练和微调监管 RAG 系统,以自动化合规性检查并加速提交文件的生成。
全球监管事务中的人工智能市场在 2024 年的估值为13.1 亿美元,预计到 2033 年的复合年增长率将达到 18.60%。尽管由于 Europlaz 及其客户之间的数据所有权分割以及法规对数据完整性的严格要求而存在访问复杂性,但本数据集具有非凡的价值。高增长的市场凸显了能够简化和降低监管审批流程风险的数据的强烈需求,这使得协商访问成为 MedTech 领域人工智能开发商的战略重点。⚠ 尽职调查(有价值的数据,可协商访问):数据所有权可能在 Europlaz(流程/遥测)及其医疗客户(产品设计)之间分割;严格的监管合规性(ISO 13485)要求严格的数据完整性,并可能限制外部共享;制造数据可能存储在孤立的 ERP 或质量管理系统 (QMS) 中 · 公司:独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Europlaz 持有其医疗器械制造的监管和质量文件的专有数据集,包括详细的可追溯性记录。对于寻求训练模型以用于监管 RAG 应用的监管科技和合规人工智能供应商来说,这是一个高价值资产。在全球监管事务中的人工智能市场预计每年增长超过 18% 的情况下,本数据集提供了一个稀有的真实世界、ISO 13485 合规文本数据来源,以建立竞争优势。
See dimension details ↓- Dataset Specificity78
主导的“监管”,医疗保健行业,2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求旺盛,这得益于在快速增长的监管事务人工智能市场(复合年增长率为 18.60%)中实现合规自动化和加速提交的需求。该市场正在迅速扩张。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility28
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度,独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型,3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
所有权=混合,许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号(2 种类型)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ 良好目标 — Europlaz 是一家英国的医疗器械合同制造商,使其成为一个强有力的目标,作为其核心运营业务的副产品,它产生了大量休眠的监管和制造数据。问题:员工人数数据在不同来源之间不一致,一个来源引用了 22 名员工,另一个来源提到了“120 名员工”。较高的数字是主要
- Deep Qualification80
✓ 通过 — Europlaz 是一家医疗器械合同制造商,因此“监管记录数据集”作为副产品具有高度可信度。然而,数据所有权在 Europlaz 及其客户之间是混合的,工作的保密性质使得第三方数据许可权不明确,并且可能受到非公开协议的限制。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
这些证据指向来自全方位制造过程的时间序列数据,为相关的监管申报提供了关键的运营背景。
Regulatory records
这些文本数据包括在ISO 13485:2016 标准下维护的全面质量记录和可追溯性日志,是训练和验证监管人工智能模型的首要来源。
business_records
这些是详细说明设备和过程验证服务(IQ、OQ、PQ)的结构化文档,为人工智能训练提供了合规程序的具体、真实世界的示例。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Europlaz Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global AI in Regulatory Affairs market = $1.31 billion in 2024, CAGR 18.60% (source: Grand View Research). Investment score 63.7/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Pan Biotech — 监管记录数据集机会
View opportunity →工业Polykemi — 监管记录数据集机会
View opportunity →医疗保健Lacollectemedicale — 监管记录数据集机会
View opportunity →